Floatz logo

Eloxatin

Liver Metastasis Colon Cancer

Fudan UniversityPhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

33 Active assets in the Liver Metastasis Colon Cancer cohort.

Asset / SponsorPhaseRating
Fruquintinib
Peking University
Phase 3BBB
DEXAMETHASONE
Fudan University
Phase 3BB
Capecitabine
Jun Huang
Phase 3BB
Irinotecan
Jun Huang
Phase 3BB
Floxuridine
Fudan University
Phase 3BB

View all 50 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →